Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Pseudotyping" patented technology

Pseudotyping is the process of producing viruses or viral vectors in combination with foreign viral envelope proteins. The result is a pseudotyped virus particle. With this method, the foreign viral envelope proteins can be used to alter host tropism or an increased/decreased stability of the virus particles. Pseudotyped particles do not carry the genetic material to produce additional viral envelope proteins, so the phenotypic changes cannot be passed on to progeny viral particles.

Envelope glycoprotein for transduction of NK cell pseudotyped lentiviral vector and application thereof

The invention discloses an envelope glycoprotein for packaging a transduction NK cell pseudotyped lentiviral vector and application of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasm region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; an amino acid sequence or a mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; an amino acid sequence or a mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentivirus pseudovirus, the high virus titer 7.33 E + 07 TU / mL is maintained, the NK cells can be effectively recognized, the virus can be mediated to enter the cells, and therefore the purpose of efficiently transfecting the NK cells is achieved.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

Purification method of BaEV enveloped pseudotype lentivirus

The invention belongs to the technical field of biology, and particularly relates to a purification method of BaEV envelope pseudotype lentivirus. The purification method comprises the following steps: (1) concentrating BaEV envelope pseudotype lentivirus clarified liquor, centrifuging, and discarding supernatant to obtain lentivirus precipitate; (2) resuspending the lentivirus precipitate with a buffer solution, and adding all-potent nuclease for enzyme digestion to obtain a crude pure sample; (3) performing chromatographic purification on the crude pure sample to obtain a refined pure sample; and (4) carrying out ultrafiltration concentration and sterilization on the purified sample to obtain the purified BaEV enveloped pseudotype lentivirus. The infection titer and the titer recovery rate of the BaEV envelope pseudotype lentivirus purified by the method are obviously improved, and host cell protein, host cell DNA and endotoxin residues can be effectively reduced. According to the purification method, impurities are effectively removed, meanwhile, the activity of the purified lentivirus is not affected, and the purification method can be used for preparing a BaEV pseudotype lentivirus product with high titer and high purity.
Owner:CHENGDU RONGSHENG PHARMA

Chimeric envelope glycoprotein, preparation method of chimeric envelope glycoprotein, envelope plasmid related to chimeric envelope glycoprotein, packaging method and kit

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.
Owner:NANJING HONGMING BIOTECHNOLOGY CO LTD +2

Pseudotyped viral particles comprising engineered chimeric receptor proteins

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. As provided for herein, the viral particles further comprises a nucleic acid molecule encoding for a heterologous molecule of interest. As provided for herein, the heterologous molecule of interest may be a tandem CAR. Also provided for herein are compositions comprising the same, and methods of using the same.
Owner:INTERIUS BIOTHERAPEUTICS INC

Envelope glycoprotein for transduction of NK cell pseudotyped lentiviral vector and application thereof

The invention discloses an envelope glycoprotein for packaging a transduction NK cell pseudotyped lentiviral vector and application of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasm region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; an amino acid sequence or a mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; an amino acid sequence or a mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentivirus pseudovirus, the high virus titer 7.33 E + 07 TU / mL is maintained, the NK cells can be effectively recognized, the virus can be mediated to enter the cells, and therefore the purpose of efficiently transfecting the NK cells is achieved.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

BaEV-G envelope glycoprotein, optimization method thereof, envelope plasmid related to envelope glycoprotein, packaging method and kit

The invention provides BaEV-G envelope glycoprotein, an optimization method of the BaEV-G envelope glycoprotein and an envelope plasmid, a packaging method and a kit which relate to the BaEV-G envelope glycoprotein, and particularly relates to the optimization method of the BaEV-G envelope glycoprotein, chimeric BaEV-G envelope glycoprotein, a lentivirus envelope plasmid, a pseudotyped packaging method of lentivirus and the kit. The BaEV-G envelope glycoprotein and the VSV-G envelope glycoprotein are chimeric to obtain the chimeric BaEV-G envelope glycoprotein, and the properties of lentivirus packaging efficiency, biological activity and the like can be effectively improved.
Owner:NANJING HONGMING BIOTECHNOLOGY CO LTD +2

Chimeric envelope glycoprotein, preparation method of chimeric envelope glycoprotein, envelope plasmid related to chimeric envelope glycoprotein, packaging method and kit

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.
Owner:NANJING HONGMING BIOTECHNOLOGY CO LTD +2

Method for preparing antibody

The present invention relates to the field of antibody preparation, and specifically relates to a method for preparing an antibody in vivo in a subject. The method comprises administering a pseudotyped lentiviral vector or a retroviral vector to a subject, wherein the pseudotyped lentiviral vector or the retroviral vector comprises an exogenous polynucleotide encoding an antigen and a viral glycoprotein or a functional fragment thereof, and the antigen is able to specifically bind to the antibody.
Owner:SHENZHEN GENOCURY BIOTECH CO LTD

Envelope glycoprotein for pseudotyped lentiviral vector for transduction of NK cells and use of envelope glycoprotein

Disclosed in the present invention are an envelope glycoprotein for packaging a pseudotyped lentiviral vector for transduction of NK cells and a use of the envelope glycoprotein. The envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasmic region, wherein the amino acid sequence or the mutation sequence of the extracellular region is as shown in SEQ ID NO: 1 or SEQ ID NO: 2; the amino acid sequence or the mutation sequence of the transmembrane region is as shown in SEQ ID NO: 3 or SEQ ID NO: 4; and the amino acid sequence or the mutation sequence of the cytoplasmic region is shown as SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. A BaEV envelope glycoprotein mutant replaces VSV-G to package a lentiviral pseudovirus, so that a high virus titer of 7.33E+07 TU / mL is maintained, NK cells can be effectively recognized, and entry of viruses into the cells can be mediated, thereby achieving the objective of efficiently transfecting the NK cells.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD

Synthetic variants of the rabies virus glycoprotein g for the generation of pseudotyped baculovirus and use thereof in Anti-rabies vaccine formulations

PCT designated stageWO2026019333A1Viral antigen ingredientsAntiviralsViral glycoproteinGlycoprotein G
The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.
Owner:FARMACOLOGICOS VETERINARIOS S A C

Affinity peptide ligand for separation and purification of VSV-G pseudotype lentiviral vector and application of affinity peptide ligand

The invention discloses an affinity peptide ligand for separation and purification of a VSV-G pseudotype lentiviral vector and application of the affinity peptide ligand. The affinity peptide ligand contains an amino acid sequence combined with a VSV-G pseudotype lentiviral vector envelope protein; the amino acid sequence is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. A biological raw material solution containing VSV-G pseudotype lentivirus vector components flows into the affinity chromatography medium, and after adsorption and cleaning, a target vector can be collected through a mild elution step; the recovery rate of virus vector particles is 78% or above, the removal rate of Vero host cell impure protein is 90% or above, the double-stranded DNA residue is 48% or below, and the separation effect is very remarkable.
Owner:TIANJIN UNIV

Bispecific antibodies to ebola virus glycoprotein and their use

PendingUS20250333484A1Immunoglobulins against virusesAntibody ingredientsBispecific monoclonal antibodyAntigen binding
A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 (“A09”). The EBOV GP bispecific monoclonal antibody (mAb114×A09 or BiSp107) exhibits synergistic neutralization of pseudotyped virus expressing EBOV GP compared with the neutralization capacity of the combination of the individual parental antibodies. Methods for pre- and post-exposure prophylaxis and treatment are described.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

A baev-g envelope glycoprotein, its optimization method, and an envelope plasmid, a packaging method, and a kit involving the envelope glycoprotein

The application provides a BaEV-G envelope glycoprotein, an optimization method thereof, and an envelope plasmid, a packaging method and a kit related to the envelope glyprotein, in particular, relates to an optimization method of a BaEV-G envelope glyprotein, a chimeric BaEV-G envelope glyprotein, a lentivirus envelope plasmid, a lentivirus pseudotyped packaging method and a kit. The BaEV-G envelope glyprotein is chimerized with the VSV-G envelope glyprotein to obtain the chimeric BaEV-G envelope glyprotein, so that the lentivirus packaging efficiency, biological activity and other performances can be effectively improved.
Owner:NANJING HONGMING BIOTECHNOLOGY CO LTD +2

Single domain antibodies directed against human transmembrane- serine protease 2 (tmprss2)

The invention relates to the discovery that TMPRSS2 acts as a functional receptor for HKU1. TMPRSS2 triggers HKU1 spike-mediated cell-cell fusion and viral pseudotype infection. Catalytically inactive TMPRSS2 mutants do not cleave spike but allow infection, demonstrating that HKU1 binding and processing represent two distinct functions of the receptor. TMPRSS2 binds with high affinity to HKU1 receptor binding domain (RED), but neither to OC43 nor to SARS-CoV-2. Conserved amino acids were identified within the RED that are essential for binding to TMPRSS2 and infection. Anti- TMPRSS2 VHH antibodies were generated that inhibit HKU1 spike binding to TMPRSS2, fusion and infection.
Owner:INST PASTEUR +1

Pseudotyped virus particles, compositions containing same, and uses thereof

Provided herein are mutant VSV-G polypeptides, compositions comprising same, and methods of using same.Also provided herein are polypeptides and compositions that bind CD7, and uses thereof.Also provided herein are polypeptides and compositions that bind CD8, and uses thereof.
Owner:INTERIUS BIOTHERAPEUTICS INC

Composition and method related to antiviral therapeutic agents

PendingKR1020260113078AIn vivoCell penetration
Formulas for use in enhancing the transduction efficiency of lentiviral vector (LV) particles into various target cells are disclosed herein. For example, a formulation for use in enhancing the transduction of paramyxovirus pseudotype lentiviral vector particles into target cells may comprise a cell-permeable peptide (CPP) comprising at least one of Vectofusion-1 or LAH4-C; and poloxamer 407, wherein the concentration of poloxamer 407 is greater than or equal to the concentration of CPP. Additionally, a method of using such formulations to enhance the transduction of LV particles, including particularly in vivo transduction, is disclosed herein.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

Pseudotyped viral particles, compositions comprising the same, and uses thereof

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
Owner:INTERIUS BIOTHERAPEUTICS INC

Method for screening and identifying pig embryo implantation key genes

The invention relates to the technical field of gene expression and regulation, and discloses a method for screening and identifying a pig embryo implantation key gene, which comprises the following steps: bioinformatics identification, embryo collection and culture. According to the method for screening and identifying the key genes for pig embryo implantation, the env gene in a pig genome is analyzed, and expression differences between normal and SCNT embryos and placentas are analyzed by utilizing bulk transcriptome sequencing, so that two candidate syncytin genes are screened; structural analysis finds that Sus1 and Sus2 have classical syncytial gene structures, expression analysis finds that Sus1 is highly expressed in an early embryo zygote genome activation stage, Sus2 is only expressed in placenta and lung and placenta-specific high expression is achieved, it is revealed that Sus1 and Sus2 may mediate porcine embryonic development and play an important role, and cell fusion and pseudotype virus test verification finds that Sus1 and Sus2 have a significant effect on porcine embryonic development. The Sus1 and the Sus2 can promote cell fusion and mediate virus entry, which further shows that the Sus1 and the Sus2 may participate in early embryonic development and placenta formation processes.
Owner:NORTHWEST A & F UNIV

Pharmaceutical compositions comprising viral particles and methods of using the same

Provided for herein are pharmaceutical compositions comprising a virus, such as lentiviruses, including pseudotyped lentiviruses and uses thereof. Also provided for herein are methods of using the pharmaceutical compositions.
Owner:INTERIUS BIOTHERAPEUTICS INC

Methods for selectively modulating activity of distinct subtypes of cells

To provide methods for selectively modulating the activity of distinct subtypes of cells.SOLUTION: The invention relates to a pseudotyped retrovirus-like particle or retroviral vector comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family, one fused to a cell-targeting domain and the other fused to a functional domain. The invention also relates to the use of the pseudotyped retrovirus-like particle or retroviral vector that selectively modulates a specific subset of cells, in particular activities of specific immune cells. The pseudotyped retrovirus-like particle or retroviral vector is particularly useful for gene therapy, immunotherapy and / or vaccination.SELECTED DRAWING: None
Owner:エコールノルマルシュペリウールドゥリヨン +3

Synthetic variants of the rabies virus glycoprotein g for the generation of pseudotyped baculoviruses and their use in anti-rabies vaccine formulations

PendingCO20260008938A2Viral glycoproteinGlycoprotein G
The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing genetic fragments from the ectodomain of the Pasteur variant rabies virus glycoprotein G, a 7-amino-acid connector sequence (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the baculoviral protein gp64, the arrangement of which in the designed gene cassette is shown in Figure 1.
Owner:FARMACOLOGICOS VETERINARIOS S A C

Pseudotyped viral particles, compositions comprising the same, and uses thereof

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.
Owner:INTERIUS BIOTHERAPEUTICS INC

Cd7 and cd3 dual targeting fusion proteins and uses thereof

The application discloses a CD7 and CD3 double-targeting fusion protein and application thereof. Specifically, the application discloses an isolated fusion protein, which comprises, from N-terminal to C-terminal, (a) an anti-CD7 single-domain antibody (CD7 VHH); (b) an anti-CD3 single-domain antibody (CD3 VHH); and (c) a transmembrane region, which is used for anchoring the fusion protein on a cell membrane or a viral envelope. And a T cell-targeting pseudotyped lentiviral vector based on the fusion protein is constructed. The pseudotyped lentiviral vector of the application can effectively target and activate T cells, and can deliver the expression CAR-containing vector into T cells, thereby effectively activating T cells and enhancing the target killing ability of T cells.
Owner:TIANYIKANG PHARMACEUTICAL (SHANGHAI) CO LTD

AAV-5 pseudotype vectors for gene therapy of neurological diseases

The present invention relates to methods of treating diseases affecting motor function (e.g., motor function affected by diseases, brain and / or spinal cord injuries) using an adeno-associated virus (AAV) gene therapy vector comprising an adeno-associated virus 5 (AAV5) capsid protein and a gene product of interest flanked by an AAV ITR. In particular, the gene therapy vectors of the invention are administered by injection into cerebrospinal fluid (CSF), preferably by lumbar injection and / or injection into the cerebellar medullary pool.
Owner:UNOCAL IP LTD

Modified rhabdovirus glycoproteins and uses thereof

The present disclosure provides recombinant fusogenic proteins comprising a rhabdovirus glycoprotein (G) and a targeting molecule attached to the N-terminus of the rhabdovirus glycoprotein. Further provided are related recombinant polynucleotides, host cells, and pharmaceutical compositions. Recombinant viruses, e.g., recombinant pseudotyped viruses, and cell-derived nanovesicles comprising the recombinant polynucleotides are also provided. Further provided are methods for using the recombinant fusogenic proteins, polynucleotides, viruses, and cell-derived nanovesicles, and / or pharmaceutical compositions thereof, including their use in the treatment of cancer.
Owner:REGENERON PHARMACEUTICALS INC +1

Novel viral particle and use thereof

PCT designated stageWO2026051968A1Immunoglobulin superfamilyGenetic material ingredientsViral envelopeCellular receptor
Provided is a pseudotyped viral particle, a viral envelope surface thereof comprising immune cell-targeting molecules and / or immune cell-activating molecules. Corresponding targeting molecules are designed on the basis of cell receptors to be targeted, enabling targeting of different types of cells. The application scope is broad, including but not limited to the rapid preparation of CAR-T, CAR-NK, and other immunotherapeutic cells in vitro without the need for sorting and activation, as well as the direct generation of CAR-T, CAR-NK, and other immunotherapeutic cells in vivo.
Owner:SHENZHEN IMMUNOFOCO BIOTECHNOLOGY CO LTD +2

Pseudotyped lentiviral vectors

PendingJP2025501550AFungiSsRNA viruses positive-senseSevere acute respiratory syndrome coronavirusVirus
Owner:IMPERIAL COLLEGE INNVOATIONS LTD

Method for screening and identifying cattle and sheep embryo implantation key genes

The invention relates to the technical field of gene expression and regulation, and discloses a method for screening and identifying cattle and sheep embryo implantation key genes, which comprises the following steps: bioinformatics identification, reverse transcription PCR (polymerase chain reaction), PCR amplification, fluorescent quantitative PCR, cell line construction and cell fusion test. According to the method for screening and identifying the cattle and sheep embryo implantation key genes, the expression difference between normal and cloned animal placentas is analyzed by analyzing env genes in cattle and sheep genomes and utilizing bulk transcriptome sequencing, candidate syncytin genes are screened, and the candidate syncytin genes are analyzed through the structure and expression, so that the cattle and sheep embryo implantation key genes are obtained. The typical functional characteristics of the cattle and sheep syncytial gene are identified through cell fusion and pseudotype virus tests, the key cattle and sheep syncytial gene is found in a cattle and sheep genome for the first time, the function of mediating placenta fusion promotion by the cattle and sheep syncytial gene is disclosed, receptors combined with the cattle and sheep syncytial gene are verified as ASCT1 and ASCT2, and the cattle and sheep syncytial gene can be used for identifying the cattle and sheep syncytial gene. And a new theoretical basis is provided for solving the problems of pregnancy failure and low somatic cell cloning efficiency.
Owner:NORTHWEST A & F UNIV